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                                        INTRODUCTION
                       Chronic liver disease (CLD) and its sequelae form a major part  
of gastroenterological workload in any large hospital. As well known, it is a 
disease with very high degree of morbidity and mortality. In the past, CLD was 
broadly divided into alcoholic and post hepatitis varieties. Over the years, with 
the  advent  of  newer  techniques  for  identification  of  viruses,  biochemical 
markers, and newer histopathological methods, it is now possible to enlarge the 
classification and attach more informative labels to such cases. Even among 
virus related CLD, a large group so far labeled as Non A, Non B, identification 
of  Hepatitis  C   has  become an  established practice.  Transfusion  associated 
NANB hepatitis has a new perspective now. Despite these transformations, a 
small proportion of patients fail to demonstrate any known viral marker raising 
further questions.
                            There are now well documented studies on the beneficial  
effects  of antiviral  agents  in the management of  chronic hepatitis  B and C. 
Hence it becomes almost mandatory to determine if a given case of CLD is 
virus related or not, so that a decision regarding the use of such antiviral agents 
can be made. Another problem, which is assuming importance, is co-existence 
of more than one hepatotropic virus. While the co-infection or superinfection of 
HBV and Hepatitis  D Virus (HDV) is  well  studied,  the  significance of  the 
presence of viral makers of HBV and HCV in the same patient is not yet clear. 
Which agent is responsible for the observed liver damage and how the presence 
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of one virus alters the biological behavior of other, are questions which have 
already caught the attention of hepatologists worldwide.
                             The frequent demonstration of viral markers in alcoholic  
liver disease (ALD) raises fresh dilemmas. Golding et al., stress the importance 
of establishing the presence or absence of Hepatitis viruses before dubbing the 
case as Alcoholic liver disease. Conditions which have been earlier passed off 
as Cryptogenic liver cirrhosis or as ALD need to be reevaluated now in the 
light of prevalence of high degree of viral markers in them.
                               Reports have begun to appear regarding the histopathology  
of  Chronic  Hepatitis  C.  Though  not  pathognomonic,  the  appearances  are 
claimed to be distinct and characteristic, Hence there is need for correlation of 
HCV markers with histopathology and substantiating such observations.
With reference to HBV, the immunological aspects have been so well studied 
and understood that there is a distinct clinical significance for the presence or 
absence of each viral antigen and antibody. Moreover, the recent demonstration 
that even patients with anti HBe, who were believed to have a good prognosis 
till now, can still harbor HBV DNA and may develop severe disease, has given 
fresh insight into this aspect.
                                 Another important aspect in CLD is its prevention and 
control. Now that effective vaccination against HBV is available, identification 
of viral etiology is of great value in protecting the family members and other 
contacts against the disease.
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Even  in  an  established  case  of  chronic  hepatitis  B,  there  may  be  sudden 
exacerbation  or  unexplained clinical  deterioration,  which  may  be  related  to 
alteration in serological status or superinfection with Delta or HCV. .
                             Hence in summary, more accurate categorization of CLD  
based on known etiological markers is essential for the following reasons:
i. Presence of viral markers in CLD  presumed to be of non viral etiology..
ii. Presence  of  multiple  viral  markers  as  well  as  non  viral  etiological 
factors in the same patient.
iii. Detection  of  Hepatitis  C  as  an  important  cause  of  CLD  as  well  as 
transfusion related hepatitis.
iv. Availability of effective anti viral drug regimens.
v. Availability of prophylactic measures to prevent the disease in family 
contacts
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BACKGROUND AND LITERATURE 
REVIEW
Role of Viruses in Chronic liver Disease:
The  viruses  associated  with  CLD,  Cirrhosis  and  Hepatocellular 
carcinoma are Hepatitis B,C and D as per our current knowledge. Blumberg 
discovered the ‘Australia Antigen’ in 1965 in an Australian aborigine. Since 
then,  there  has  been  a  steady  evolution  of  knowledge  regarding  hepatitis 
viruses  and their  mechanisms of  liver  injury.  It  is  extremely  fascinating  to 
know that  these  viruses  by  themselves  are  not  cytopathic  and yet  they  are 
responsible for devastating hepatic injury. 
HEPATITIS B VIRUS
Virology
Hepadnaviruses
                    HBV is a member of a family of distinct viruses, known as the  
Hepadnaviridae, which infect humans and a few animal species (duck, ground 
squirrel, and woodchuck). Characteristics of these viruses include the presence 
of partially double-stranded DNA that is surrounded by an outer  lipoprotein 
envelope  and  an  inner  core  composed  of  nucleocapsid  proteins.  The  virus 
encodes  a  polymerase  that  catalyzes  by  reverse  transcription  both  the 
generation of DNA complementary to the viral RNA template and the synthesis 
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of positive-strand viral DNA from the negative-strand DNA template of the 
virus these viruses are all predominantly hepatotropic.
Structure:
             HBV is a remarkably compact virus with four open reading frames  
(ORF) (S,P,C,and  X protein, respectively). Intact HBV virions are 42 nm in 
diameter  and  are  readily  visualized  by  electron  microscopy.  HbsAg,or  S 
protein, which is 24 kD in size, is the major envelope protein of the virus.S1 
region,  is  believed  to  play  a  role  in  binding  virus  to  a  receptor  on  the 
hepatocyte  surface.  Within the  envelope is  a  27-nm structure  known as the 
nucleocapsid core, which consists of 180 copies of the viral core protein, or 
hepatitis B core antigen (HBcAg),surrounding the viral DNA and the virally 
encoded  polymerase.  The  viral  polymerase functions  as  both  a  reverse 
transcriptase for synthesis of the negative DNA stand from genomic RNA and 
an endogenous DNA polymerase. The HBV polymerase, is encoded by the  P 
gene of  the  virus,  the  function  of  the  X protein appears  to   function  as  a 
transcriptional  activator  that  influences  the  transcription  of  HBV  genes  by 
regulating the activity of transcriptional promoters.
Genomic Organization
Despite  its  small  size  (3.2  kb),HBV encodes  four  major  proteins:  the 
surface, core, and X proteins and the polymerase. This compactness is 
achieved by the use of overlapping ORFs so that more than one half of 
the  nucleotides  are  used  in  a  different  frame  for  the  transcription  of 
different viral messenger RNAs (mRNAs). The precore region contains a 
signal  sequence  that  directs  the  protein  to  the  endoplasmic  reticulum 
where host  proteases  cleave much of the C-terminus  of  the protein to 
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form HbeAg, which is  subsequently excreted from the cell.  These  so-
called  “precore  mutants”  in  humans  are  associated   with  active  viral 
replication  (readily  detectable  HBV  DNA  in  serum),  lack  of  HbeAg 
production,  and  progressive  liver  disease.  In  light  of  the  cross-
immunoreactivity  between HBcAg and HbeAg,  a  possible  function  of 
HbeAg is to divert the immune response of the host away from virally 
infected hepatocytes that express HBeAg on their surfaces. HbeAg is also 
a marker of active viral replication. Production of high levels of HBeAg 
is indicative of synthesis of large amounts of full-length genomic mRNA, 
which in turn reflects active viral replication.
Replication
The life cycle of HBV includes the following steps.
1. Viral binding and entry
2. Viral uncoating in the cytoplasm
3. Synthesis of complete double-stranded DNA in the nucleus
4. Synthesis  of  genomic  or  pregenomic  RNA  and  viral  transcripts 
necessary for viral protein production
5. Translation of viral transcripts
6. Encapsidation
7. Reverse transcription and synthesis of DNA strands
8. Envelopment
In contrast to classical retroviruses such as HIV, integration of HBV DNA into 
the host genome is not necessary for viral RNA synthesis, and HBV transcripts 
are  synthesized entirely  from episomal  DNA. The  unique life  cycle  of  this 
family of viruses affords opportunities for the development of antiviral agents.
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Epidemiology
Incidence and Prevalence
                  Chronic hepatitis B is a common disease with an estimated global  
prevalence of over 300 million carriers, or approximately 5% of the world’s 
population.  In  the  Far  East  the  Middle  East,  Africa,  and  parts  of  South 
America, the prevalence is high, with HBeAg positivity rates ranging from 8% 
to 15%. Regions of intermediate prevalence (2%-7%) include Japan, parts of 
South  America,  Eastern  and  Southern  Europe,  and  parts  of  central  Asia. 
Prevalence is lowest (<2%) in the United States and Canada, Northern Europe, 
Australia, and the southern part of South America.
Transmission
HBV is parenterally transmitted via blood or blood products or by sexual or 
perinatal exposure, the same routes as for HIV.
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Perinatal and Early Childhood Transmission
                 Infants born to HBeAg-positive mothers who have high levels of 
viral  replication  (HBV DNA level>80  pg/mL)  have  a  70% to  90% risk  of 
perinatal  acquisition in  the  absence of  interventions.  The risk of  mother-to-
infant  of  transmission  from HBeAg-negative  mothers  is  substantially  lower 
(10%-40%).
Sexual Transmission
                Sexual activity is probably the single most important mode of HBV 
transmission  in  areas  of  the  world  such  as  North  America,  where  the 
prevalence of infection is low.
Heterosexual sex, now accounts for the majority of cases of HBV infection 
(26%) with an identifiable risk factor in the United States. Sexual partners of 
injection drug users,  prostitutes,  and clients  of prostitutes are at particularly 
high risk of HBV infection. Studies of sexual and household contacts of HBV 
carriers have shown that 0% to 3% of the spouses or sexual partners and 4% to 
9% of the children are HBsAg positive. 
Injection Drug Use
In the United States and Western Europe, injection drug use remains a very 
important mode of HBV transmission (23% of all cases)
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Other Modes of Transmission
Other risk factors for HBV infection include working in a health-care setting, 
transfusions and dialysis, acupuncture, tattooing, travel abroad, and residence 
in a an institution.
Pathogenesis
Immune Pathogenesis
Clinical observations suggest that the immune response of the host is more 
important than viral factors in the pathogenesis of liver injury caused by HBV, 
Chronic HBV carriers  who have normal liver enzyme levels  and normal or 
near-normal  liver  histologic  studies,  despite  high  levels  of  viral  replication. 
Infants with immature immune systems who acquire HBV infection at birth 
have a high rate of chronic infection and replication yet typically have only 
mild  liver  injury.  Conversely,  HBV  induced  fulminant  hepatic  failure  is 
associated with a vigorous immune response, low serum levels of virus, and 
massive hepatocellular necrosis.  It  has  been widely accepted that  CTLs are 
responsible  for  destruction  of  virally  infected  hepatocytes  and  for  viral 
clearance. However,, the number of CTLs involved is generally much fewer 
than the number (10  11) of virally infected hepatocytes. Thus, secondary non-
antigen-specific immune responses, such as those mediated by inflammatory 
cytokines, may be more important for viral clearance than the CTL-mediated 
mechanism. Recent data point  to the importance of tumor necrosis  factor-α 
(TNF-α)  and  gamma-interferon  as  prime   mediators  of  this  non-antigen-
specific clearance of HBV.
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Chronic Infection
With  chronic  infection,  HBsAg,  HBeAg,  and  HBV  DNA  remain 
positive for 6 months or longer. After the acute phase of infection, serum ALT 
levels fall but often remain persistently abnormal (from 50 to 200 U/L). IgM 
anti-HBc titers typically fall to undetectable levels after 6 months IgG anti-HBc 
persists during the acute and chronic phases of disease. With time, there may 
be a spontaneous loss of HBV DNA and HBeAg, frequently in association with 
a  flare  of  serum  ALT  levels  and  seroconversion  to  anti-HBe  positivity. 
Spontaneous loss of HBeAg  is rare. Anti-HBs may be detected simultaneously 
with HBsAg in serum in fewer than 10% of cases. The presence of anti-HBs is 
associated with immunity to HBV infection. Isolated anti-HBs is more likely to 
be acquired by vaccination than by natural infection, in which both anti-HBs 
and IgG anti-HBc are typically present. Fifty percent of patients with chronic 
HCV infection are anti-HBc positive .
Diagnosis
Serologic assays for the diagnosis of acute and chronic infection .HBV 
DNA quantification is  generally performed by signal or target amplification 
tests: the liquid hybridization test uses a liquid phase to hybridize I-HBV DNA 
after  the sample HBV DNA has been denatured. The lower detection limit of 
the assay is 1-2 pg/mL or 6x105 copies/mL. The RNA -DNA hybrid assay has a 
sensitivity of 0.018 pg/ mL or 5 x105 copies/mL.The branched DNA assay the 
sensitivity  limit  is  7  x  105 DNA  equivalents/mL.  The  polymerase  chain 
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reaction  (PCR)  assay is based on the amplification of viral DNA, performed 
automatically in the Cobas analyzer after the manual extraction of viral DNA 
performed automatically in the (Cobas Amplicor HBV Monitor the sensitivity 
of the Cobas-Amplicor assay is between 100 and 400 copies/mL, and that for 
the Taqman method is as low as 10 copies/mL; both assays are more sensitive 
than the branched DNA and Genostics assays.
Complications
Patients with chronic HBV infection are at risk of developing long-
term complications of portal hypertension and hepatic decompensation, such as 
variceal bleeding, ascites, and hepatorenal syndrome, as well as HCC. Patients 
with chronic liver disease, particularly those with established cirrhosis, are at 
increased risk of developing HCC.the risk of developing HCC is increased 10- 
to 390-fold in patients with chronic HBV infection compared with those who 
are  HBsAg  negative  and  is  greater  in  those  who  acquired  HBV  infection 
perinatally than in those who acquired the infection as adults. Cirrhosis of the 
liver  is  present  in  more  than  90%  of  patients  with  HCC  related  to  HBV 
suggesting that the presence of cirrhosis is a risk factor for HCC development. 
Chronic  inflammation associated  with active  viral  replication,  together  with 
ongoing  cellular  proliferation  and  regeneration  associated  with  cirrhosis,  is 
likely  a  predisposing  factor  that  leads  to  cellular  transformation  and  frank 
malignancy.
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Co infection with Other Viruses
              Risk factors for acquisition of HBV infection are similar to those for  
acquisition  of  HIV infection.  Both  viruses  have  an  increased  prevalence  in 
persons with multiple sexual partners and in injection drug users. In contrast, 
sexual transmission of HDV and HCV is relatively inefficient. Markers of prior 
or active HBV infection are present in more than 80% of patients with HIV 
infection, approximately 10% of whom are HBsAg positive. Conversely, HIV 
infection can be prevalent in patients with chronic HBV infection.
Pathology
As with other chronic viral  hepatitides,  HBV infection is  associated with a 
predominantly lymphocytic infiltrate that may or may not be confined to the 
portal tracts. Characteristic of chronic HBV infection is the presence of ground-
glass hepatocytes, in which the cytoplasm is stained pink with hematoxyline 
and eosin, reflecting the massive overproduction of HbsAg in these chronically 
infected cells/
Natural History
Chronic  HBV  infection  is  usually  defined  as  detectable  hepatitis  B 
surface antigenemia for a period of six months or more. The risk of chronic 
infection is related to two major factors: the age at which infection is acquired 
and  the  immune  state  of  the  host.  Detection  of  HBV  DNA  by  sensitive 
molecular techniques. Infectious virions can clearly be detected in patients who 
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are HBsAg negative. The risk of chronicity after acute HBV infection is low in 
immunocompetent  adults.  The reported risk of  chronic  infection after  acute 
exposure in adults ranges from less than 1% to 12%, but the consensus is that 
the risk of chronicity is less than 5%. The risk of chronic infection is greatly 
increased in patients who have a reduced ability to recognize and clear viral 
infection  (e.g.  patients  on  chronic  hemodialysis,  those  on  exogenous 
immunosupperssion following solid organ transplantation, and those receiving 
cancer  chemotherapy).patients  with  concomitant  HIV  infection  are  also  at 
significant  risk  of  developing  chronic  infection  (20%-30%  )the  risk  of 
chronicity after neonatally acquired infection is extremely high (up to 90%). 
Presumably  because  neonates  have  an  immature  immune  system.  Cirrhosis 
develops in 15% to 20% of them within 5 years, even if histologic liver damage 
is initially mild. Many patients with chronic HBV infection have normal serum 
aminotransferase levels, normal or near-normal liver histology findings, and no 
symptoms. These “inactive  carriers” appear to be immunologically tolerant of 
the virus, and their prognosis is excellent.
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HEPATITIS C VIRUS
Hepatitis C virus (HCV) is a major cause of chronic hepatitis, cirrhosis 
and HCC and a major indication for liver transplantation worldwide. The most 
striking feature of this virus is its ability to induce persistent infection is at least 
85% of infected  persons despite a vigorous humoral and cellular host immune 
response.
Virology
Structure
HCV  consists  of  a  positive-strand  RNA  surrounded  by  the  core 
(nucleocapsid),which is surrounded by two envelope proteins (E1 and E2). The 
negative strand of HCV RNA , is produced as a replicative intermediate during 
replication and is acknowledged to be a marker of ongoing viral replication.
Genomic Organization
HCV is a single-stranded positive-sense RNA virus that belongs to the 
Flaviviridae  family.  The  positive-strand  RNA  of  HCV  has  three  potential 
function:1)as  a  template  for  synthesis  of  negative-strand  RNA  during 
replication,2)as a template for translation of viral proteins, and 3) as genomic 
RNA to be packaged into new virions. In contrast to HBV,HCV has no DNA 
intermediate and therefore cannot integrate into the host genome.
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Genotypes and Quasispecies
Like many RNA viruses HCV has an inherently high mutation rate that 
results in considerable heterogeneity throughout the genome. Genotype, which 
refers to genetically distinct groups of HCV isolates that have arisen during the 
evolution of the virus. First variant cloned by Choo and associates is designated 
type 1a.although some studies have reported an association between genotype 1 
b  and  more  severe  liver  disease,  other  studies  have  failed  to  find  such  an 
association.  The  second  component  of  genetic  heterogeneity  is  known  as 
Quasispecies. Quasispecies are closely related yet heterogeneous sequences of 
the HCV genome within a single infected person that result from mutations 
during viral replication. The highest proportion of mutations has been found in 
the E1 and E2 regions at both the nucleotide (1.2%-3.4%) and the amino acid 
(1.4%-2.7%)levels particularly in the hyper variable region (HVR) at the amino 
terminal  end  of  E2.  The  quasispecies  nature  of  HCV  may  be  one  of  the 
mechanisms by which the virus escapes immune responses
Epidemiology
Incidence and Prevalence
The worldwide seroprevalence of HCV infection, based on antibody to 
HCV (anti-HCV),is estimated to be 3%.
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Transmission
The  modes  of  transmission  of  HCV  infection  can  be  divided  into 
percutaneous  (blood  transfusion  and  needlestick  inoculation)  and 
nonpercutaneous  (sexual  contact,  perinatal  exposure).  The  latter  group  may 
represent  occult  percutaneous  exposure.  Overall,  blood  transfusion  from 
unscreened donors and injection drug use are the two best documented risk 
factors.  In  contrast  to the  high efficiency of  perinatal  transmission of HBV 
from mothers to infants, the efficiency of perinatal transmission of HCV is low 
with a risk estimated to range from 0% to 10% the prevalence of anti-HCV 
positivity in pregnant women ranges from 0.7% to 4.4%, Perinatal transmission 
occurs exclusively from mothers who are HCV RNA positive at the time of 
delivery.  The risk posed to the infant from breast-feeding is  believed to be 
negligible.
Clinical Manifestations and Diagnosis
Acute and Chronic Infection
HCV accounts for approximately 20% of cases of acute hepatitis. Acute 
infection is, however, rarely seen in clinical practice, because the vast majority 
of patients experience no clinical symptoms. HCV RNA appears in the blood 
within  2  weeks  of  exposure  and  is  followed  by  an  increase  in  serum 
aminotransferase levels several weeks later. HCV infection is self-limiting in 
only 15% of patients in whom HCV RNA in serum becomes undetectable and 
ALT levels return to normal. Approximately 85% of infected patients do not 
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clear  the  virus  by  6  months,  and  chronic  hepatitis  develops.  Of  these  the 
majority will have elevated or fluctuating serum ALT levels, whereas one third 
have persistently normal ALT values.
Diagnostic Tests for Hepatitis C
I. Serologic assays
1. Screening assays
            EIA-1
EIA-2
EIA-3
2. Confirmatory assays (RIBA)
II. Virologic assays
1. HCV  RNA detection
               Qualitative
   Quantitative
    PCR –based methods
   BDNA assays
2. Genotyping
3. Analysis of HCV quasispecies
Diagnosis
Selection of Serologic and Virologic Tests
      Initial diagnostic testing of HCV infection is currently made by detecting 
specific antibody by second or third- generation EIA tests for low-risk patients, 
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a negative EIA test result is sufficient to exclude HCV infection. For high risk, 
recently exposed, or immunocompromised patients (including HIV-infected, 
chronic hemodialysis, and transplant patients), further confirmatory testing is 
required. For years, confirmation was performed using RIBA testing. PCR 
testing has supplanted the RIBA test as the confirmatory test of choice. 
Pathology
The range of histologic findings in patients with chronic HCV infection 
is broad, from minimal periportal lymphocytic inflammation to active hepatitis 
with  bridging  fibrosis,  hepatocyte  necrosis  and  frank  cirrhosis.  Steatosis, 
lymphoid aggregates,  and bile duct damage are frequent in the liver biopsy 
specimens from patients with HCV infection, but there is considerable overlap 
with  the  histologicfindings  in  patients  with  chronic  HBV  infection  and 
autoimmune  hepatitis.  The  Histologic  Activity  index  (HAI)  developed  by 
Knodell and associates is still used to quantity the degree or liver damage .A 
simplified system in which inflammation is graded from 0 t 4 and fibrosis is 
staged from 0 to  4 has  been developed by Scheuer and colleagues.  Recent 
consensus conferences have stated that a liver biopsy is mandatory in patients 
with chronic hepatitis C and elevated serum aminotransferase  levels so that 
correct grading and staging can be performed. This information is particularly 
relevant  when  considering  antiviral  therapy  or  when  other  causes  of  liver 
disease may be present.
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Natural History
Infection with HCV, once established, persists in the vast majority of 
patients. Disease progression is largely silent, and patients often are identified 
only on routine biochemical screening or blood donation.
Studies of Patients with End-Stage Disease
(Cross-Sectional Studies)
Evaluation of  patients  with established chronic hepatitis,  cirrhosis,  or 
non-HBC  HCC  with  use  of  antibody  assays  provides  evidence  for  an 
association between HCV infection and liver disease. Anti-HCV is detectable 
in 8% to 69% of patients with cryptogenic cirrhosis, with most studies finding 
rates of approximately 50%. Anti-HCV is  also detectable in 6% to 76% of 
persons with HCC.
Prospective Studies
These studies provide unequivocal evidence of the progressive nature 
ofchronic  HCV  infection.  Infections  often  can  be  sub  clinical,  and  in 
symptomatic patients, fatigue is the most frequent complaint. Cirrhosis, defined 
histologically  or  clinically  is  present  in  8%  to  42%  of  patients.  In 
approximately  10%   of  cases,  decompensated  disease  was  present,  with 
splenomegaly, ascites, coagulopathy, and esophageal varices. If the data from 
all these studies are combined, we can conclude that when the entire population 
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of  HCV-infected  persons  is  observed,  only  a  small  percentage  have  serve 
outcomes during the first two decades of infection.
Factors Associated with Disease Progression
Age (older  than  40 years),male  gender,  and increased  alcohol  intake 
(>50  g  daily)  have  been  documented  as  variables  associated  with  disease 
progression.  Immunosupperssion  is  clearly  linked  with  more  aggressive 
disease. Other less consistently documented prognostic factors include mode of 
transmission  (higher  disease  progression  when  infection  is  through  blood 
transfusion than through injection drug use) and coinfection with HBV.
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ALCOHOLIC LIVER DISEASE
EPIDEMIOLOGY
Alcohol is  one of the most openly available and generally consumed 
mood-altering substances. Patterns of intake vary among different geographic 
regions. Men who drink more than 80 g of ethanol per day are at substantial 
risk for  development  of  clinical  liver  disease.  Liver  disease in  women who 
drink excessively is two to four times more likely to develop than in men who 
drink excessively. The risk of liver disease begins at relatively low levels of 
alcohol  consumption  (30  g/day),  this  finding  has  led   to  a  general 
recommendation  that  the  maximal  safe  level  of  ethanol  consumption  is  20 
g/day of ethanol, or two “drinks” per day, even among those who ingest large 
amounts of alcohol(more than 60 g /day),serious liver disease develops in only 
approximately 1 in 10. When disease occurs, it can take many form, ranging 
from steatosis, to alcoholic hepatitis, to hepatic fibrosis or cirrhosis, because 
disease severity does not correspond to classic dose dependency, other factors 
are  likely  to  play  an  important  role  in  pathogenesis.  These  factors  may  be 
hereditary, environmental, or both.
ETHANOL METABOLISM
Hepatic metabolism
The liver is the primary site of ethanol metabolism. Within the liver, 
ethanol can be oxidized by three enzyme systems: the alcohol dehydrogenases 
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(ADHs),  cytochrome  P-4502E1  (CYP2E1),  and  catalase.  Both  ADH  and 
CYP2E1 convert  ethanol  to  acetaldehyde.  Acetaldehyde is  then oxidized to 
acetate, primarily by a low- Km.
 Aldehyde  dehydrogenase  in  hepatocyte  mitochondria  designated  ALDH2. 
Acetaldehyde is a highly reactive and potentially toxic metabolite of ethanol. If 
the ability of the lover to remove acetaldehyde is decreased, acetaldehyde can 
accumulate  in  the  liver  and  in  the  circulation.  Acetaldehyde  produces 
symptoms of flushing and tachycardia and can provoke circulatory collapse. 
Persons who are homozygous for the mutant enzyme experience severe side 
effects from acetaldehyde and thus rarely consume ethanol.
Gastric Metabolism:
Although the liver is the primary site of alcohol metabolism, ethanol can 
also be oxidized in the gastrointestinal tract. Gastric ADH has been implicated 
in a so-called gastric  first-pass metabolism of  ethanol;  by oxidizing ethanol 
directly in the stomach, this enzyme may limit the amount of ingested ethanol 
that is delivered to the portal circulation.
Gastric ADH activity is lower in women than in men and can also be 
inhibited by certain drugs, such as aspirin and histamine H2 receptor blockers. 
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PATHOGENESIS OF ALCOHOLIC LIVER INJURY
Toxic and Metabolic Mechanisms
Redox Alteration.ADH – mediated ethanol oxidation is accompanied by 
the reduction of oxidized nicotinamide-adenine dinucleotide(NAD+) to reduced 
NAD (NADH) . Excess NADH shifts the redox state of hepatocytes, which in 
turn affects other NAD+ -dependent processes, including lipid and carbohydrate 
metabolism. One consequence of the redox shift is hepatic steatosis.
NADH also interferes with gluconeogenesis. In patients who have underlying 
carbohydrate malnutrition can lead to profound hypoglycemia.
Chronic  ethanol  consumption,  however,  can  prolong  the  redox  shift  by 
damaging hepatocyte mitochondria and preventing reoxidation of  NADH to 
NADl.
OXIDANT STRESS: 
Ethanol oxidation leads to formation of several free radical species in 
the liver, including the hydroxyethyl radical, the superoxide anion(O2-), and the 
hydroxyl radical (OH.). These free radicals can inflict oxidative damage on a 
wide range of intracellular compounds. Radical formation has classically been 
considered  a  consequence  of  ethanol  oxidation  by  CYP2E1.Recurited 
leukocytes can also contribute to alcohol-induced oxidant stress. Neutrophils, 
which figure prominently in alcoholic hepatitis, are stimulated by ethanol to 
produce superoxide radical.
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The effects  of  radicals  on the  liver  may be amplified if  ethanol also 
reduces antioxidant defenses. Chronic alcohol consumption causes depletion of 
several antioxidants in the liver, including vitamins A and E and glutathione.S-
adenosyl-methionine  (SAMe),  a  glutathione  precursor,  can  replete 
mitochondrial glutathione stores and correct some of the functional alterations.
HYPOXIA: 
      Another means by which ethanol may preferentially damage pericentral 
hepatocytes is through tissue hypoxia. The hypermetabolic state enhance the 
portal-to-central oxygen gradient, leaving pericentral hepatocytes in a state of 
relative  hypoxia,  Pericentral  hypoxia  has  been  documented  in  human 
alcoholics.
EFFECTS OF ACETALDEHYDE:
               If acetaldehyde reaches a high enough concentration, it can become a  
substrate  for  the  enzymes  aldehyde  oxidase  and  xanthine  oxidase,  which 
produce free radicals.  Acetaldehyde impairs mitochondrial  beta oxidation of 
fatty acids can also react with specific amino acid residues on cellular proteins 
to form acetaldehyde-protein adducts. The adducts localize preferentially to the 
pericentral  zone,  where  liver  injury  is  most  pronounced.  Aldehyde-protein 
adducts may contribute to alcoholic liver disease by forming neoantigens that 
stimulate  immune  responses  or  by  promoting  hepatic  collagen  synthesis. 
Acetaldehyde-induced impairment of protein secretion implicated as the major 
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event  underlying  hepatocellular  swelling  (“ballooning”)  in  alcoholic  liver 
disease.
IMMUNE AND INFL. MECHANISMS OF LIVER INJURY
KUPFFER CELL ACTIVATION AND CYTOKINE PRODUCTION:
Kupffer cells, which are the resident macrophages of the liver, produce 
oxidants  and  cytokines  for  the  purpose  of  host  defense.  Chronic  ethanol 
consumption causes abnormal activation of Kupffer cells. In this setting, the 
cytokines and oxidants elaborated by these cells can inflict damage on the liver 
itself.
Among  the  many  compounds  produced  by  activated  Kupffer  cells, 
tumor  necrosis  factor  (TNF),  transforming  growth  factor-β(TNF-β),  and 
superoxide appear to be the most pertinent to alcoholic liver injury.
IMMUNE  RESPONSES  TO  ALTERED  HEPATOCELLULAR 
PROTEINS:
             If  hepatocellular proteins form adducts with either aldehyde or 
hydroxyethyl  radicals,  they  can be altered sufficiently  to  provoked immune 
responses.
Mechanisms of Fibrosis
Liver fibrosis  is  a serious and potentially irreversible consequence of 
chronic ethanol use. Fibrosis occurs in only 10% to 15% of alcoholics but can 
be found in  almost  50% of  alcoholics  who have evidence  of  liver  disease. 
Central  to  the  pathophysiologic  mechanisms  of  alcoholic  liver  fibrosis  is 
activation  of  hepatic  stellate  cells.Activated  stellate  cells  are  the  principal 
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collagen  producing  cells  of  the  liver.  They  are  responsible  for  the 
perisinusoidal fibrosis that is characteristic of alcoholic liver disease.
COFACTORS  IN  THE  DEVELOPMENT  OF  ALCOHOLIC  LIVER 
DISEASE:
Heritable Factors
Studies have focused on polymorphisms in ADH, CYP2E1, and ALDH 
which together cause a wide range of ethanol elimination rates. Asians who 
inherit  the  slower  allele,  ADH2*,  tend  to  consume  more  alochol65 and 
experience  more  liver  disease  than  those  with  ADH2*2.  Unlike  ADH,  the 
CYP2E1 allele associated with liver disease is the one that encodes the more 
active enzyme.
For  ALDH,  the  mutant  allele  ALDH2*2  has  been  implicated  in  the 
development of alcoholic liver disease. ALDH2*2 homozygotes have a strong 
aversion to ethanol caused by acetaldehyde toxicity. Among patients who have 
alcoholic  liver  disease,  those  with  TNFA-A  had  twice  the  frequency  of 
steatohepatitis of those without TNFA-A.
Gender
Women are more susceptible to serious alcoholic liver injury than men. 
They also exhibit a tendency toward disease progression even with abstinence. 
One  theory  implicates  the  reduced  levels  of  gastric  ADH  in  women  as  a 
causative  factor.  Accelerated  alcoholic  liver  injury  in  women  also  may  be 
related to gender-specific differences in fatty acid metabolism.
Diet and Nutrition.
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In  human  beings,  however,  alcoholic  liver  injury  appears  to  be 
influenced strongly by nutritional status.Both undernutrition and overnutrition 
have  been  implicated  as  risk  factors  in  the  development  of  alcoholic  liver 
disease.  Obesity  is  now  well  recognized  as  an  independent  risk  factor  for 
hepatic  steatosis  and  steatohepatitis.  When  alcohol  consumption  is 
superimposed on obesity, the risk of liver disease rises almost six fold.
In  addition  to  fat  and  calories,  dietary  iron  can  influence  the 
development of liver disease in alcoholics. Chronic ethanol ingestion promotes 
absorption of iron from the intestine, and over time hepatic iron stores increase. 
It can contribute to liver disease by enhancing the oxidant stress.
Coexistent Viral Hepatitis.
18% to 25% of alcoholics are infected with the hepatitis C virus (HCV) . 
In alcoholics with liver disease, the frequence of HCV infection is even higher. 
The combination of alcohol and HCV infection significantly accelerates the 
progression  of  liver  disease  over  that  seen  with  either  insult  alone.  This 
association may be related to the effects of alcohol on HCV replication or on 
the host immune response to the virus.
Like  HCV,  hepatitis  B  virus(HBV)  accelerates  the  progression  of 
alcoholic  liver  disease.  Epidemiologic  surveys  indicate  that  HBV infection 
hastens mortality in alcoholics.
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DIAGNOSIS:
Alcohol should be strongly suspected as a cause of liver disease in any 
patient  who consumes more than 80 g/day of  ethanol.  Confounding factors 
such  as  gender  or  HCV  infection  warrant  consideration  of  alcoholic  liver 
disease even in individuals who consume two drinks of ethanol daily.
Laboratory Findings.
Atleast 75% of patients with alcoholic liver disease have a macrocytic 
anemia.  Leukocytosis  is  also  common.  AST and ALT levels  rarely  exceed 
300U/L and do not correlate well with disease severity.
The AST/ALT ratio often exceeds 2 in patients who have alcoholic liver 
disease.  A ratio  greater  than or  equal  to 3 strongly  suggests  alcoholic liver 
disease.
The  high  AST/ALT  ratio  in  alcoholics  with  liver  disease  has  been 
attributed to pyridoxine deficiency, which cause a reduction in the AST and 
ALT content of hepatocytes, and disproportionate reduction in ALT content.
The  serum  bilirubin  level  and  prothrombin  time(PT)  are  useful 
predictors of the severity of liver disease in alcoholics. Maddrey and associates 
also used the bilirubin level and PT to generate a “discriminant function” that 
identifies patients who have a significant short-term mortality rate:
Disciminant  function=  4.6x(PT  in  seconds  –  control  in  seconds)  +  
bilirubin(mg/dL)
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A discriminant function greater than 32 predicts a 1-month mortality rate of 
approximately 50%. 
Histology
Liver  biopsy  is  viewed  by  many  authorities  as  the  standard  for 
diagnosing alcoholic  liver  injury  useful  for  diagnosis  and for  prediction  of 
prognosis.  Among  the  most  common  histologic  features  of  alcoholic  liver 
disease  are  (1)  steatosis  ,(2)ballooning  degeneration  of  hepatocytes,  (3) 
presence of Mallory’s bodies, (4)neutrophilic inflammation, and (5) pericellular 
fibrosis .
Steatosis is present in 60% to 95% of alcoholic liver disease patients. 
Macrovesiculur steatosis is the rule.
Fibrosis,  which  occurs  in  50%  to  75%  of  patients  who  have 
alcoholic liver injury, begins with deposition of connective tissue around the 
terminal  hepatic  venule  and  then  extends  into  the  hepatic 
parenchyma(“chicken-wire”  fibrosis).The  cirrhosis  that  evolves  is 
micronodular.
In 1991, Chedid and colleagues definded four histologic categories of 
alcoholic  liver  disease  for  the  purpose of  predicting  survival  (1)  fatty  liver 
(FL), (2) alcoholic hepatitis(AH), (3) cirrhosis, and (4) cirrhosis with alcoholic 
hepatitis(C+AH). The two main criteria used to stratify patients into the four 
categories were hepatic inflammation (absent in FL and present in AH) and 
cirrhosis (present in C and C+AH but not in FL or AH)
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COMPLICATIONS
Ascites,  gastrointestinal  hemorrhage,  and  encephalopathy, 
hypoalbuminemia  and  hypoprothrombinemia.When  alcoholic  liver  disease 
progresses to cirrhosis, hepatocellular carcinoma (HCC) may develop. Alcohol 
alone appears to be an independent risk factor for HCC, albeit a weaker one 
than viral hepatitis. Among alcoholics, men older than 50 years of age appear 
to be most vulnerable to development of HCC.
NONALCOHOLIC STEATOHEPATITIS:
 
Nonalcoholic steatohepatitis (NASH) is a form of chronic hepatitis with 
histological  features of alcohol-included liver  disease that  occurs in persons 
who do not consume a significant amount of alcohol. 
 NASH is considered to be part of the spectrum of NAFLD. NAFLD is 
an uncommon disorder that occurs most often in middle-aged obese women. 
Obesity,  hyperglycemia,  and  hyperlipidemia  are  commonly  associated  with 
NAFLD and are thought to be predisposing conditions, Other identified risk 
factors  include  total  parenteral  nutrition,  protein-calorie  malnutrition, 
jejunoileal (J-I) bypass, and use of certain drugs.
Ultrasonographic  surveys  of  the  general  population demonstrate  fatty 
liver in about 25% of adults in the United States. NAFLD is the most common 
explanation  for  an  elevated  serum alanine  aminotransferase  (ALT)  level  in 
blood donors. The prevalence of NAFLD in the general population parallels the 
prevalence of obesity and insulin resistance, the most common risk factors for 
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this  type  of  liver  disease.  Progression  to  cirrhosis  does  occur.  Advanced 
fibrosis or cirrhosis on liver biopsy specimens in up to two thirds of patients 
with  NAFLD who were  older  than  age  45  years  and  had  type  2  diabetes, 
obesity or hypertriglyceridemia. Clinical manifestations of portal hypertension, 
hepatic  failure,  and  hepatocellular  carcinoma  may  develop  in  patients  with 
NAFLD and significant hepatic fibrosis. In a 1999 series, liver disease was the 
second leading cause of health in patients with NAFLD.
ETIOLOGY
Divided  into  two  broad  categories:  (1)  drugs  and  toxins  and  (2) 
metabolic abnormalities either acquired or congenital. Most published series of 
patients with NAFLD emphasize a predisposition to steatohepatitis in middle-
aged  women  who  are  obese  or  who  have  non-insulin-dependent  diabetes 
mellitus or hyperlipidemia.
Several mechanisms have been proposed as causes of NASH, including 
amino acid imbalance, hyperglycemia (caused by diabetes mellitus or excessive 
administration of glucose), excessive circulating levels of anabolic (eg. insulin) 
relative  to  catabolic  (eg..leptin)  hormones,  and  endotranslocation).  Each  of 
these  processes  can  shift  metabolism  to  favor  net  lipogenesis  rather  than 
lipolysis, because hepatitis and cirrhosis are much less frequent than steatosis 
can provoke histologic progression to cirrhosis or that an additional insulates 
necessary to produce this outcome. 
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Similarities in the histologic features and natural histories of alcoholic 
liver disease and NAFLD suggest that common mechanism may be involved in 
the pathogenesis of these two disorders that chronic oxidative stress also may 
be involved in the pathogenesis of NAFLD.
Inpatients with NAFLD, the content of ethanol in the breath increases 
progressively with body mass index and is independent of serum liver enzyme 
levels  or  histological  evidence  of  fibrosis.  These  findings  suggest  that 
endogenous ethanol might promote the earliest stage of obesity-related NAFLD 
(i.e., steatosis).
Serum and  adipose  tissue  levels  of  TNF-α are  increased  in  obesity, 
steatohepatitis  occurs  commonly  in  obese  patients  who have  undergone  j-1 
bypass  surgery  and  in  patients  receiving  long-term  total  parental  nutrition 
(TPN);
Most  patients  with  NAFLD  are  asymptomatic.  NAFLD  is  often 
diagnosed after serum liver biochemical abnormalities are noted during routine 
laboratory  testing.  Hepatomegaly  has  been  noted  in  up  to  three  fourths  of 
patients in several studies. Stigmata of portal hypertension appear to occur less 
frequently, although splenomegaly was noted at the time of diagnosis in about 
25% of the patients in one series.
Laboratory Findings
The suspicion of NAFLD is usually prompted by abnormal serum liver 
biochemical  findings.  Increased  serum  alanine  aminotransferase(ALT)  and 
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aspartate  aminotransferase(AST)  activity  is  the  predominant  laboratory 
abnormality. Usually the levels of ALT, AST, or both, are mildly to moderately 
increased, and the serum levels of these enzymes cannot be used to predict the 
histologic severity of hepatic inflammation or fibrosis. Patients with NAFLD 
usually  have  an  AST/ALT ratio  of  less  than  1.Increases  in  serum alkaline 
phosphatase  and  gamma-glutamyl  transpeptidase  (GGTP)  levels  are  not 
uncommon in patients with NAFLD. Hyperbilirubinemia, prolongation of the 
prothrombin time and hypoalbuminemia are noted infrequently in most series.
                  Abnormal serum lipid profiles and elevated serum glucose 
concentrations  are  also  common  in  patients  with  NAFLD  and  have  been 
reported in 25% to 75% of cases. 
A diagnosis of  NAFLD can be established only in patients who do not 
consume significant  amounts  of  alcohol.  Incidence  of  alcohol-induced liver 
disease  begins  to  increase  only  after  certain  “threshold”  levels  of  alcohol 
consumption (i.e.20 g/day of ethanol in  women and 80 g/day of ethanol in 
men) are exceeded habitually.
There is no perfect test to identify alcohol use, particularly in the 
context of underlying liver disease. The ratio of dTf  to total Tf appears to be 
the  best  single  marker  of  chronic  excessive  alcohol  consumption  in  such 
patients. A dTf/Tf ratio of 1.3% or greater was a reliable indicator of excessive 
chronic alcohol consumption.
Testing to exclude viral hepatitis has become a prerequisite for 
the diagnosis of NAFLD. Although HCV infection does not cause NAFLD, 
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NAFLD may increase the severity of HCV-related liver damage. Regression 
analysis has identified hepatic steatosis as an independent predictor of cirrhosis 
in  patients  with  chronic  hepatitis.  Obesity-related  steatosis  has  the  same 
ominous  prognostic  implications  as  alcohol-induced  steatosis  in  patients 
infected with HCV.
Noninvasive  imaging  techniques,  including  ultra-sonography, 
computed tomography, and magnetic resonance imaging (MRI), can identify 
hepatic  steatosis.  Of  these,  phase  contrast  MRI  appears  to  be  the  most 
promising,  because  its  results  correlate  well  with  the  degree  of  histologic 
steatosis. None of these imaging techniques is sufficiently sensitive to detect 
hepatic inflammation, fibrosis, or cirrhosis. Therefore liver biopsy remains the 
best diagnostic test for confirming the clinical suspicion of NAFLD and staging 
the severity of liver injury and fibrosis.
A 1999 study from the Mayo Clinic  suggested that  older  age, 
obesity, diabetes mellitus, and a serum AST/ALT ratio greater than 1 can help 
identify a subset of patients with NAFLD who are most likely to have severe 
fibrosis indicated on liver biopsy.
HISTOLOGIC FEATURES
The major  histologic  features  of  NAFLD resemble  those  of  alcohol-
induced liver disease and include steatosis (fatty liver),  steatohepatitis (fatty 
liver  plus  parenchymal  inflammation  with  or  without  accompanying  focal 
necrosis), and variable degrees of fibrosis (including cirrhosis). As in alcoholic 
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liver  disease,  steatosis  in  NAFLD  is  predominantly  macrovesicular  and 
generally distributed diffusely throughout the liver lobule. As in patients with 
alcohol-induced liver disease, fibrosis can progress to cirrhosis in NAFLD. In 
both, steatosis is the principal early finding, but episodes of steatohepatitis can 
punctuate  the  course,  and  eventually  cirrhosis  develops  in  some  affected 
persons.
Role of Liver Biopsy
The  combination  of  the  history,  physical  examination,  noninvasive 
blood tests, and imaging studies is useful for excluding other diseases as an 
explanation for abnormal liver enzyme levels. Liver biopsy is seldom necessary 
simply to diagnose NAFLD, which is currently a diagnosis that is made by 
excluding other causes of chronic hepatitis in patients with fatty liver. Liver 
biopsy is the most sensitive and specific means to stage patients with NAFLD.
PROGNOSIS
Emerging evidence suggests  that clinically significant liver disease is 
probably no more rare in NAFLD than in chronic hepatitis C or other types of 
chronic hepatitis. Evidence from Caldwell and colleagues in 1999 suggests that 
NAFLD is likely to have been the underlying liver disease for most patients 
with cryptogenic cirrhosis.NAFLD may be as important  a cause of cirrhosis in 
the United States as alcohol or hepatitis C infection.
Study on the presentations of chronic liver disease in correlation to their 
etiologies in inpatients in Government General Hospital, Chennai.
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AIM
 To study about the various clinical, biochemical and pathological 
presentations of chronic liver disease and to estimate their relative frequencies.
1. To estimate the contribution of hepatitis virus B & C in causing chronic 
liver disease in an urban setup
2. To find out the relative prevalence of NASH in patients diagnosed to 
have chronic liver disease (CLD)
OBJECTIVE
     The study was conducted with following specific objectives in mind.
1. What is the relative frequency of clinical, biochemical, pathological 
abnormalities found in chronic liver disease of various etiologies
2. What is the prevalence rate of HBV and HCV in patients with CLD
3. Should NASH be considered to be an emerging risk for CLD in urban 
population ?
PATIENTS & METHODOLOGY
          The study was conducted in Government General Hospital, Chennai, 
during the period September 2003 to August 2004.
      100 consecutive adult patients admitted to the male and female wards of 
Medical Gastroenterology ward diagnosed to have CLD  (by criteria given 
below) were included in the study.
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INCLUSION CRITERIA
1. Symptoms of parenchymal liver disease for more than 6 months in the 
form of continuous or fluctuating jaundice, unexplained asthenia, poly 
arthralgia, fever, anorexia, pruritus in association with significant 
elevation of transaminases or histopathological evidence of chronic 
hepatitis
2. High SAAG ascites with evidence of portal hypertension by clinical, 
and ultra sound examination complemented by Doppler whenever 
required
3. Evidence of portal hypertension with histopathological evidence of 
cirrhosis or chronic active hepatitis
4. Persistent elevation of transaminases in patients symptomatic over a 
period of 6 months
Portal hypertension was deemed to exist in the presence of esophageal or 
gastric varices during GI endoscopy, anterior abdominal wall veins with flow 
away from the umbilicus, ultra sound evidence of collateral venous circulation 
and portal vein diameter of > 1.1 cm with or without splenomegaly.
EXCLUSION CRITERIA
1. Patients diagnosed as acute viral hepatitis, resolving within 6 months
2. Liver secondaries with known or unknown primaries.
3. Obstructive jaundice as evidenced by ultrasound, or ERCP
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4. Cases diagnosed  to have Budd-Chiari syndrome, VOD, EHPVO or non 
cirrhotic portal hypertension.
5. Portal hypertension without ascites where liver biopsy could not be done
6. Cases where EHPVO or NCPF could not ruled out with certain after 
exhaustive testing
    Thus 100 consecutive cases satisfying the above criteria were included in the 
study comprised of   males and   females. The youngest was aged 15 years and 
the oldest being 65 years. All patients hailed from Chennai city or its suburbs 
within 75 km radius.
       A careful and complete history, as well as clinical examination as per 
proforma was performed. Following investigations were done for all patients. 
        Complete blood counts, Bleeding time, Clotting time, Prothrombin time, 
Urinalysis, Stool examination for parasite and occult blood, Blood Sugar, Urea, 
Electrolytes, Creatinine, Serum Bilirubin SGOT, SGPT, Alkaline Phosphate, 
Total protein, Albumin, Globulin, Ascitic fluid protein, albumin, SAAG, 
amylase, cell count and cytology, Chest X ray, USG abdomen, Doppler study 
of portal venous system  (in selected cases), UGI endoscopy, liver biopsy (in 
selected cases).
         Samples were sent to Department of Microbiology, Madras Medical 
College and to Dr.A.L.Mudhaliar Post Graduate Institute of Basic Medical 
Sciences, Taramani, Chennai for testing viral markings for HBV and HCV.
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         Liver biopsies were done using biopsy gun under ultrasound guidance 
with standard precaution after obtained informed consent. Liver biopsy could 
not be done in   some patients due to massive ascites, coagulopathy, HE or 
other moribund state. The histopathology examination and reporting were done 
by Institute of Pathology, Madras Medical College. 
           Amount of ethanol intake, frequency and type were noted and so also 
about other drug usage.
   
         In selected patients where Wilson’s disease was suspected slit lamp 
examination for KF ring and serum Ceruloplasmin level were estimated. Alfa 
protein levels were estimated in patients when imaging studies have shown 
presence of nodule or clinical suspicion of HCC was strong. 
DEFINITIONS
Non alcoholic fatty liver disease (NASH) is defined as a form of chronic 
hepatitis with histological features of alcohol induced liver disease who do not 
consume significant amount of alcohol.
Obesity is diagnosed when BMI (Body mass index) is more than 30 
Diabetes mellitus is diagnosed when fasting blood sugar exceeds 126 mg/ dl or 
when post-prandial blood sugar level exceeds 180 mg/dl
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Hepatitis B was diagnosed when HbsAg found positive. HbeAg and anti 
HbeAg were done in selected cases.
Hepatitis C infection was diagnosed with positive anti- HCV antibodies and 
abnormal LFT. HCV RNA was done in selected cases
(ELISA, Zhongshan Biotech Co. China)
HCC ( Hepatocellular Carcinoma) was diagnosed with USG/ CT findings and 
elevation of Alfa feto protein levels. Liver biopsy was done in some patients 
whenever feasible.
Wilson’s disease was diagnosed by positive KF ring in cornea and low serum  
ceruloplasmin levels. 
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RESULTS
The  100  patients  of  chronic  liver  disease  could  be  classified  on 
clinicopathological as well on etiological basis. On clinic pathological grounds 
the patients could be divided as follows:  
Decompensated cirrhosis - 60
Compensated cirrhosis - 24
NASH - 3
HCC - 3
CAH - 10
Total - 100
Based  on  the  evaluation  of  viral  markers,  alcoholic  intake,  previous 
blood  transfusion  and copper  studies  in  a  few cases,  the  patients  could  be 
grouped into several categories as follows:
Group A :   Positive for only alcohol - 23
Group B :   Positive for only HBV - 22
Group C :   Positive for only HCV -   3
Group D :   Postive for both HBV & alcohol - 15
Group E :   Positive for both HCV & alcohol  -   1
Group F :   NASH   -   3
Group G :    Cryptogenic   - 28
Group H :   Miscellaneous  - Wilson’s Disease  -   5
Total 100
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ETIOLOGICAL GROUPS
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CLINICOPATHOLOGICAL GROUPS
24%
60%
3%
3%
10%
COMPENSATED
DECOMPENSATED
NASH
HCC
CAH
Each etiological group could be split up into the clinicopathological 
groups as already mentioned.
On comparing the variables, in the age group of 15-35 yrs, alcohol was 
the  only etiology detected,  where as both HBsAg and anti  HCV antibodies 
were  not  found.  In  the  age  group  of  36  –  60years  alcohol  was  the  only 
aetiology in 15 patients, both alcohol and HBV were present in 15 patients and 
both alcohol and HCV were present in 1 patient. In the age group of > 60years, 
alcohol was the only etiology in 3 patients and again in this age group, there 
was no viral markers detected.
When comparing alcohol abuse and sex, alcohol alone had been detected 
as etiological factor in 21 male patients and 2 females and combined HBV & 
alcohol was present in 13 male patients and 2 female patients.  Alcohol and 
HCV was detected as the etiological factor in 1 male patient.
Regarding distribution of various etiological factors in the 3 age groups, 
HBV alone was responsible in 5, 16 and 1 in the age groups of 15-35, 36-60 
and >60 years respectively. Both HBV and alcohol was more common in the 
age group of 36 – 60years, cryptogenic cirrhosis was more common in the age 
group of 36-60 years, where it is present in 17 patients. Cryptogenic cirrhosis 
was present in 3 and 8 patients respectively in the age group of 15-35 years and 
>60 years respectively. NASH was common in the age group of 36 – 60 yrs.  
All the 3 cases in this study belonged to that age group. Regarding Wilson’s 
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disease , all the 5 patients belonged to the age group of 15 – 35 years. All HCV 
related cirrhosis belonged to the age group of 36 – 60 years.
Regarding  the  sex  and  etiological  factors,  cryptogenic  cirrhosis  was 
present  in  20 female  and 8 male  patients.  Wilson’s  disease  was present  as 
aetiology in 2 females and 3 male patients. All the three NASH patients were 
females.  All  HCV related  cirrhosis  were  found  in  male  patients.  All  HCV 
related CLD were found in the age group of 36 – 60 years.
Regarding NASH, all the 3 patients belonged to the age group of 36 – 
60 years. All the 3 NASH patients were females.
In the characterization of Wilson’s disease by age and sex, it was all 
found in the age group of 15 – 35 yrs, and 3 patients were male and 2 patients 
were female.
Among the 3 cases of HCC recorded alcohol abuse was present in one 
patient only, even that was along with HBV. In HCC, HBV was present in all 
the 3 cases. In 2 patients HBV alone was present as the etiological factor and in 
1  patient it was present along with alcohol.
In  NASH,  all  the  3  patients  were  obese.  Hypertriglyceredemia  was 
present in 2 out of 3 patients and diabetes was present in one patient.
In HCV related CLD, thrombocytopenia was present in all the 4 cases.
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In cryptogenic cirrhosis, Hypertriglyceredemia was found in 16 out of 
28 patients and diabetes was found in 13 out of 28 patients. Promiscuity was 
found  in  3  patients  of  cryptogenic  cirrhosis.  15  out  of  28  patients  with 
cryptogenic cirrhosis were obese.
13  patients  received  blood  transfusions  in  the  past.  The  transfusions 
were mostly for UGI bleeding, post surgery or unknown indications. It was not 
possible to ascertain whether  blood transfused came from related donors or 
professional  donors.  All  the  13  had  some  identifiable  etiological  factor  to 
explain the CLD. 
Histopathology 
Liver  biopsy  was performed  in  49  patients.  Satisfactory  results  were 
available in 41 patients. The rest being reported as “inadequate tissue”. The 
histopathology  reports  were  HCC  in  3,  chronic  active  hepatitis  with  (or) 
without fatty change in 13 and varying grades of cirrhosis with (or) without 
fatty change in the rest.
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CIRRHOSIS WITH ACTIVITY – Showing inflammatory cell activity (A) in addition 
to regenerating nodule (B) and minimal fibrosis (C)
CIRRHOSIS – Showing periportal fibrosis (A) and regenerating nodules (B)
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 HEPATOCELLULAR CARCINOMA – Showing malignant hepatocytes in a 
sinusoidal arrangement
HEPATOCELLULAR CARCINOMA – High Power View
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Table – 1  : Age distribution   among various  study groups
 
ALCOHOLIC
Total
ALCOHOL 
ONLY
NON 
ALCOHOLIC
ALCOHOL
+HBV
ALCOHOL + 
HCV
AGE 15-35 5 11 0 0 16
36-60 15 41 15 1 72
>60 3 9 0 0 12
Total 23 61 15 1 100
Table – 2  :  Prevalence of  CLD due to HCV   in various age groups
 
 
AGE
Total15-35 36-60 >60
HCV +ve 0 4 0 4
-ve 16 68 12 96
Total 16 72 12 100
Table – 3  :  Distribution of NASH in different age groups
AGE
Total15-35 36-60 >60
NASH  Present 0 3 0 3
 Absent 16 69 12 97
Total 16 72 12 100
Table – 4  :  Distribution of NASH in both sexes
 
SEX
TotalF M
NASH Present 3 0 3
Absent 29 68 97
Total 32 68 100
Table – 5  :  Obesity and NASH
 
 
BMI
Totalobese nonobese
NASH  Present 3 0 3
 Absent 7 90 97
Total 10 90 100
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Table  -  6  :  NASH and Hypertriglyceridemia
 
 
HYPER TRIGLY
Total Present  Absent
NASH  Present 2 1 3
 Absent 15 82 97
Total 17 83 100
Table – 7 :  NASH and Diabetes
 
DIABETES
Total Present  Absent
NASH  Present 1 2 3
 Absent 16 81 97
Total 17 83 100
Table – 8  :  Hypertryglyceridemia in   Cryptogenic cirrhosis
 
 
HYPER TRIGLY
Total Present  Absent
CRYPTOGENIC  Present 16 12 28
 Absent 14 58 72
Total 30 70 100
Table – 9  :  Cryptogenic cirrhosis  and Diabetes
 
DIABETES
TotalPresent Absent 
CRYPTOGENIC Present 13 15 28
Absent 17 55 72
Total 30 70 100
Table – 10  :  Prevalence of obesity  in Cryptogenic cirrhosis
 
BMI
TotalObese Nonobese
CRYPTOGENIC Present 15 13 28
Absent 8 64 72
Total 23 77 100
Table – 11  :  Cryptogenic cirrhosis in various age groups
 
AGE
Total15-35 36-60 >60
CRYPTOGE
NIC
 Present 3 17 8 28
 Absent 13 55 4 72
Total 16 72 12 100
Table – 12  :  Cryptogenic cirrhosis  in both sexes
 
 
SEX
TotalF M
CRYPTOGENIC Present 20 8 28
Absent 12 60 72
Total 32 68 100
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DISCUSSION
As set out under objectives of the study, the data collected from 100 
patients was analysed with respect to the presence and distribution of various 
virological markers, clinicopathological features and other etiological factors.
From  the  results,  it  is  seen  that  39  out  of  100  were  positive  for 
significant alcohol consumption,  37 had markers  for  HBV, 4 of  them were 
positive for       anti HCV antibodies and 31 were negative for alcohol, HBV, 
HCV and blood transfusion. 
Alcoholic Liver Disease and Hepatitis B & C
39 out of the 100 patients admitted using significant amounts of alcohol 
over a period of not less than 10 years. Only in 23 patients, alcohol was the sole 
recognizable etiological  factor  and these patients  could be safety labeled as 
having alcohol induced chronic liver disease.
In the remaining 16 patients, there were additional etiological markers 
noted .15 patients had HBV and 9 patients had received blood transfusions in 
the past. Among the 9 patients with H/O Blood transfusion, alcohol was the 
sole etiological  factor in 3 patients  and HBV was the additional etiological 
factor in the remaining 6 patients. The question that arises in this group of 16 
patients having multiple etiological factors, is the relative contribution of each 
of them in the production and continuation of CLD. Even if we assume that in 
6 patients out of these 16 patients, the presence of hepatitis B viral markers is 
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incidental due to blood transfusion, in the remaining 9 patients there is no past 
h/o blood transfusion.
While there is no controversy in the role of alcohol in inducing acute 
alcoholic hepatitis and fatty liver, there is scope for discussion with reference 
to CLD and alcohol, especially HCC. The observation of patients developing 
chronic sequalae despite total abstinence from alcohol at an early stage, though 
attributed to immune mediated mechanisms, is not fully explained. Ever since 
viral  markers  become  available,  investigators  started  probing  the  probable 
relationship  between  HBV  and  alcohol  and  recently  HCV  and  alcohol 
(11,12,13). The question of  which is  incidental  (or)  co pathogen is  not  yet 
resolved. While there are several papers devoted to this subject, the paper by 
Mendenhall et al  (14) based on a multicenter VA cooperative study is worth 
reviewing. 350 patients with CLD were analyzed for the presence of HBV and 
HCV markers and compared with two other groups namely 1) no alcoholism 
nor liver disease 2) alcoholism only. While HBV prevalence was similar in all 
the three groups, HCV prevalence was significantly higher in those with liver 
disease.  The  study  of  clinical  characters  like  age,  alcohol  intake,  bilirubin, 
transaminase,  alkaline  phosphatase,  prothrombin  time  did  not  show  any 
difference between HBV positive and HBV negative groups. On the other hand 
mean bilirubin values and prothrombin time showed significant elevation in 
HCV  positive  patients  in  comparison  with  HCV  negative.  Histological 
comparisons were done using twelve criteria (six for alcoholic hepatitis and six 
for chronic viral hepatitis). Ito cell activity ,cirrhosis and all features of viral 
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hepatitis  were  significantly  more  marked  in  HCV  positive  cases.  They 
conclude that HCV and HBV markers in alcoholic liver disease have different 
clinical significance. Anti HCV antibodies correlate with clinical severity and 
histopathological changes, while HBV antibodies do not. HCV infection has an 
adverse effect on long term survival.
In our study, 23 out of 39 patients with alcohol consumption did 
not  have  any  viral  markers.  Gross  comparison  of  histopathological 
appearance of these two groups i.e. (HBV positive, HBV negative ALD) 
did not reveal any notable differences in features, hence it appears that 
alcohol  is  a  common  etiological  factor  in  CLD.  In  many  cases 
coexistence of hepatitis B was noted and in a small percentage of cases 
blood transfusion  and hepatitis  C were  associated.  With regard  to  the 
presence of Hepatitis B markers it looks as though the clinical picture and 
outcome do not differ much in the two groups. The number of patients 
positive  for  HCV  is  too  small  to  draw  any  conclusions  as  to  how 
alcoholic liver disease will be modified by coexisting HCV. 
Regarding  virological   markers  in  ALD,  serological  HBsAg may  be 
absent and serum Hepatitis B virus DNA testing may be necessary to diagnose 
hepatitis  B  infection  (15). Positive  second  generation  ELISA  tests  usually 
correlate  with  a  positive  hepatitis  C  virus  RNA  and  allow  diagnosis  of 
complicating Hepatitis C disease (16). Alcohol aggravates liver damage due to 
hepatitis C virus  (16). Viremia increases and the natural history is adversely 
affected  (17,18). The relative risk of developing cirrhosis is increased. In our 
study,  we  have  not  performed  HBV DNA in  alcohol  positive  and  HBsAg 
negative patients. Performing HBV DNA in this group may have yielded more 
HBV positive patients with alcoholic etiological background. Due to lack of 
resources we did not perform HBV DNA which is the limitation of this study.
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  CLD and Hepatitis C:
One of  the  main  aims  of  this  study is  to  estimate  the  prevalence  of 
hepatitis C virus infection in patients with CLD in general and alcohol related 
CLD in particular.  HCV accounts for 20% of acute cases,  70% of cases of 
chronic  hepatitis,  40%  cases  of  end  stage  cirrhosis,  60%  of  cases  of 
hepatocellalar carcinoma and 30% liver transplants. Only 4 patients out of 100 
had HCV antibodies implying previous infection with HCV. All cases due to 
HCV were found in the age group of 35-60 yeas. All the 4 of them were male. 
one  patient  (case  no.  25)  had  also  h/o  alcohol  consumption.  None  of  the 
patients had concomitant HBV infection. H/o blood transfusion in the past was 
present  in  none  of  the  4  patients.  All  the  4  patients  presented  with 
decompensated liver disease. None of them presented with HCC. According to 
Dinis - Ribeiro M et al, Older patients, with a shorter time interval between 
HCV infection and diagnosis, and namely those with markers of HBV infection 
represent patients with higher risk for progression to hepatic cirrhosis (19). In 
our study, the patients with HCV related CLD all belonged to the age group of 
35-60 years with mean age of 51 years. Our patients were relatively elderly, 
when  compared  to  HBV  related  and  alcohol  related  CLD.  According  to 
Fattorich G et al, patients with HBV infection may present with cirrhosis about 
10 years earlier than those with HCV infection. HCV infection also tends to be 
associated with a higher risk of decompensation(20). In our study, HBV alone 
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is the etiological factor in 5,16 and 1 patients respectively in the age group of 
15-35, 36-60 and > 60 years.
All  the  15  patients  with  both  alcohol  and  HBV  as  the  etiological  factor 
belonged to the 36-60 years age group. The mean age of the patients with HBV 
infection was 39 years which is again less than that of those with HCV related 
CLD.  Among  the  37  patients  with  HBV.  Only  8  of  them  belonged  to 
compensated liver disease. All of the 15 patients with alcohol as the additional 
etiological  factor  belonged  to  decompensated  liver  disease.  Caldwell  et  al 
reported 30% incidence of anti HCV antibody in ALD, compared to 2% in 
healthy controls and other studies  have recorded 25-52% incidence (14). In our 
study only 1 patient out of  39 with ALD had anti HCV positivity (2.6%) which 
is far lower than the figures from American and Western European studies.
In two Indian studies,  Prof  B.N. Tandon and colleagues  (13)  have reported 
about 45% incidence of HCV in CLD and Amarpurkar et al from Bombay have 
shown 17% incidence in their cases (12).
Severity of the liver disease:
All patients with cirrhosis were classified into child’s criteria into 
child A,B and C categories. The main etiological groups (Alcohol only, 
HBV only, HCV only, HBV + Alcohol, HCV + alcohol) were further 
divided  according  to  child’s  grading.  No  statistically  significant 
difference could be made out from these figures. In other words, alcohol 
and  hepatitis  B,  whether  acting  singly  or  in  combination  do  not  by 
themselves  have  any  mitigating  or  aggravating  effect  on  the  clinical 
status.  If  the  incidence  of  hepatitis  C  was higher,certainly  the  picture 
would have been different because long standing HCV infection is known 
to produce more severe liver disease, especially in ALD as per the studies 
discussed earlier.
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HCC and Viral markers:
The role of hepatitis B in HCC  is well established since long time. The 
presence of  HBV markers  in  HCC parallels  the  prevalence of  HBV in the 
general population. In countries like Taiwan, Hong Kong, Uganda, about 80-
90% of HCC are related to HBV. In Japan, when anti HCV was estimated, 70% 
of Japanese with HCC were anti HCV positive according to Nishioka (quoted 
in 14). While similar high prevalence was reported in the Western Europe (11), 
some what lower figures are reported in United States (30-54%) and Africa 
(34-54%). In China, Tsai JF et al suggested that by multivariate analysis, both 
HBsHg and anti HCV were important and independent risk  factors for HCC 
(odds ratio, 6.52 and 4.59 respectively)  (10). Asian race and patient age <50 
years were found to be independent predictors for HBs Ag positivity, while a 
history of blood transfusion was the only predictor for anti HCV positivity in 
HCC patients. Chronic HBV infection was the major etiological factor in Asian 
- American HCC patients, while chronic HCV infection and alcoholism were 
major etiological factors in Caucasian HCC patients in the USA.  (9). In our 
study, 3 patients were found to have HCC. 2 patients had HBV alone as the 
etiological factor and1 patient had  both HBV and alcohol as the etiological 
factor. None of 3 patients (patient No: 19,37 and 57) had markers for HCV. 
None of them had blood transfusions.All the 3 had been detected in  patients 
with cirrhotic background. Since IV drug abuse has been suggested as the main 
mode of transmission, this may account for low prevalence of anti HCV in 
HCC patients. It also reflects the low prevalence of HCV infection in our study 
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on CLD.  Although anti  HCV is  some what  less  sensitive  than  HCV RNA 
assay, HCV RNA assay in 16 patients with features of steatohepatitis in our 
study did not detect more number of cases attributable to HCV.
Non alcoholic steato hepatitis (NASH)
One of  the main aim of this  study is  to  evaluate the contribution  of 
NASH to CLD. Obesity, diabetes and hypertriglyceredemia are the main risk 
factors associated with NASH. The prevalence of NASH in Thai patients with 
non HBV, non HCV chronic hepatitis was 76.1%, while the liver  biopsy can 
add  the  diagnostic  yield  especially  in  the  group  of  unexplained  chronic 
hepatitis with obesity, diabetes mellitus and dyslipidemia (8).
In our study, all the 3 NASH patients were female in the age group of 36-60 
years. Among them, all of them were obese with BMI of > 30. Two out of 3 
patients had hypertriglyceredemia and 1 patient had diabetes. HCV RNA assay 
was  done  in  16  patients  including  who  were  diagnosed  as  NASH,  who 
demonstrated  variable  degrees  of  steatosis  and  steatohepatitis  on  USG and 
elevated liver enzymes and HPE. All the 16 cases were HCV RNA negative. 
The same risk factors like obesity  etc are associated with advanced hepatic 
fibrosis in patients with chronic hepatitis C. (5,6,7). All the patients had clinical 
jaundice  and  hepatomegaly.  None  of  them  had  varices  on  endoscopic 
examination. In our study, NASH contributed to only 3% cases of chronic liver 
disease. We do not know, in how many patients in cryptogenic cirrhosis group 
it contributed to the progression to cirrhosis since the some of the patients with 
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cryptogenic cirrhosis, the same risk factors like obesity, diabetes mellitus, and 
female gender are also present.
Cryptogenic cirrhosis:
The aetiology is unknown and this represents a heterogeneous group. 
Cirrhosis can be difficult to ascribe to NASH if histologic features have been 
lost  (or)  obscured  by  cirrhotic  nodules.  Such  nodules  have  been  shown 
occasionally  to  have  focal  fatty  changes  (3). Serial  biopsy  studies  have 
established the progression of NASH to a stage of “bland” cirrhosis. The loss 
of  fatty  infiltration  may  be  the  result  of  altered  blood  flow  or  decreased 
sinusoidal permeability and lipoprotein delivery as the liver becomes fibrotic. 
Results  of  epidemiologic  and  familial  studies  have  strongly  suggested  that 
many cases of “cryptogenic” cirrhosis are the result of such a process (2). The 
significantly  increased  frequency  of  steatosis  and  steatohepatitis  after 
transplantation for cryptogenic cirrhosis further supports this relation.
Frequency varies in different parts of the World. In the UK, it is about 5-10%, 
whereas in other areas like France and urban USA, the proportion is lower. The 
advent of testing for hepatitis B and C transferred many previously designated 
cryptogenic cirrhosis to the post hepatitic group. Estimation of serum smooth 
muscle and mitochondrial antibodies and better interpretation of liver histology 
separate others into the autoimmune chronic hepatitis - PBC group. Some of 
the remainder may be alcoholics who deny  alcoholism.
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According to Caldwell SH et al,  70% of cryptogenic cirrhosis were female. 
74% of them had H/o obesity and/or diabetes. Both diabetes and obesity were 
significantly more common in the cryptogenic cirrhotic patients compared with 
the cirrhotic patients with PBC (or) hepatitis C. In contrast, the prevalence of 
obesity and diabetes was similar to the NASH patients who were, on average, a 
decade younger. He concluded that NASH plays an under recognized role in 
many  patients  with  cryptogenic  cirrhosis,  most  of  whom  are  older  type  2 
diabetic and obese females (2).
Patients with advanced cryptogenic cirrhosis are more likely to be obese 
and diabetic compared with age and sex matched patients with advanced 
cirrhosis. This supports the hypothesis that NASH may be an etiological 
factor in some of the patient with CC (1,4).
 In  our  study,  Cryptogenic cirrhosis  was  present  in  20 females  and 8 
males. It was more common in the age group 36-60 years, where it is 
present in 17 patients. It was present in 3 and 8 patients respectively in 
age groups 15-35 and >60 years
              Hypertriglyceridemia was found in 16 out of 28 patients. 
Diabetes in 13 out of 28 patients and 15 patients were obese (BMI > 
30). Promiscuity was associated in 3 patients.The risk factors of 
NASH were present in majority of patients with Cryptogenic 
cirrhosis. It may be speculative that NASH may be a predisposing 
factor in the development of cirrhosis in these patients.
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SUMMARY
 
An  attempt  was  made  to  detect  the  presence  of  etiological  markers 
especially for HBV, HCV and alcohol in 100 patients of Chronic liver disease. 
The various clinical and pathological features were correlated with etiological 
factors. An attempt was made to find out the relative prevalence of NASH in 
patients diagnosed to have chronic liver disease (CLD).
The study could have been more informative and authoritative if some 
of the following technologies were routinely available - kits for HBV DNA, 
HCV RNA, electron microscopy and markers for autoimmune liver disease.
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CONCLUSIONS
1. Chronic liver disease is a major health problem in this area.
2. 60 out  of  100 patients  with CLD were related to  Ethanol  and 
HBV either singly or in combination.
3. The incidence of HCV infection is very low in this part of the 
world (4%).
4. A sizeable proportion (28%) belongs to the group of cryptogenic 
cirrhosis which calls for a lot of research in this sphere to detect 
new viruses or environmental factors responsible.
5. The prevalence of NASH in patients  with CLD is 3%
6. Obesity,  Hypertriglyceredemia  and  Diabetes  were  present  in 
patients with NASH either singly or in combination.
7. Coexistence of HBV and Alcoholic liver disease does not alter 
the histopathology or clinical severity of the illness .
8. In view of the too small number of HCV cases,  we could not 
document  the  histopathological  characteristics  claimed  to  be 
distinctive of HCV infection. 
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